ClinicalTrials.gg
RecruitingNCT06731855SuNDiALUpdated Sep 29, 2025

An Exploratory Physiological Study of Post-operative Recovery in Surgical Neonates and Dimethylarginine:Arginine Levels

An observational study in Gastroschisis, Congenital Diaphragmatic Hernia and Duodenal Atresia, sponsored by Liverpool Women's NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged Up to 5 Days. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Liverpool Women's NHS Foundation Trust · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
Up to 5 Days
Sex
All
01

Study summary

The SuNDiAL study will measure levels of two naturally occurring amino acids: Arginine and Asymmetric Dimethylarginine (ADMA) in neonates undergoing abdominal surgery in the first 5 days of life due to congenital abdominal malformations as the participants recover from surgery.

The investigators hypothesise that the relationship between Arginine and ADMA may be useful in predicting recovery and complications in babies who have had abdominal surgery due to previous research published in adult patients undergoing abdominal surgery. If this relationship is found to be useful there may be options for developing treatments (such as arginine supplementation) in the future to improve recovery and reduce complications in neonates undergoing abdominal surgery.

Neonates born after 35 weeks gestation who have a congenital abdominal malformation who require abdominal surgery in the first 5 days will be eligible to participate in the SuNDiAL study.

Arginine and ADMA will be measured from blood samples that are left over from the participant's blood tests that are taken as part of their routine clinical care. The investigators will measure Arginine and ADMA preoperatively and at least 10 points in the 30 days following their surgery, or until the participant fully recovers from surgery (which ever comes first). There is no intervention in the SuNDiAL study, and there will be no extra blood or blood samples taken.

Serums samples that are left over from the babies routine clinical blood tests will be stored securely in the hospitals laboratory until analysis for Arginine and ADMA.

The levels of Arginine and ADMA will be compared to the time it takes the participants to recover from surgery and any complications that may arise following surgery. During the study the study team will use the participants electronic medical record to establish when the participant became fully established on oral feeding and monitor for any complications that occurred during their recovery.

Read the detailed description

The study is a prospective observational, physiological study running across the two trust that form the Liverpool Neonatal Partnership; Liverpool Women's Hospital NHS Foundation Trust and Alder Hey Children's Hospital Foundation Trust.

There is no study intervention and therefore all participants will be managed in accordance with existing local protocols and current accepted clinical practice. Participants will receive standard neonatal and surgical care as per the local clinical guidelines. The participant will have routine blood tests taken as part of their routine care. No additional blood or blood tests will be taken for the SuNDiAL study.

The study will involve the analysis of any blood left over from samples taken routinely pre and postoperatively in infants who have undergone abdominal surgery. Residual serum samples will be analysed from the blood samples taken for routine blood monitoring in the infants enrolled in the study. Biochemical samples will undergo Enzyme-linked immunosorbent assay (ELISA) analysis for ADMA and arginine.

The study period is from preoperatively until 30 days post operatively or until the baby fully recovers from surgery, marked by being fully fed with milk into their stomach. The aim is to obtain at least 1 measurement preoperatively, and a minimum of 4 measurements in the post-operative period. The expectation is that 3-5 measurements first 10 postoperative days should be achievable.

The SuNDiAL study will aim to determine if the level of ADMA and/or Arginine and/or the Arginine to ADMA ratio is associated with the time taken to recover following major abdominal surgery in neonates born after 35 weeks gestation. Recovery will be measured as the time taken to no longer require intravenous nutrition following surgery as the primary objective.

The secondary objectives include:

  1. To develop a mathematical model of postoperative ADMA and/or ARG/ADMA ratio. This will allow future randomised controlled trial designs investigating postoperative recovery time to include ADMA and ARG/ADMA in the study protocol. This modelling has the potential to develop future arginine supplementation protocols to target and/or refine arginine dosage and duration based on the trajectory of the ADMA levels or arginine:ADMA ratio. This approach includes specific post operative complications following surgery that may delay recovery (such as mortality, wound healing, sepsis, parenteral nutrition cholestasis)
  2. To compare ADMA and/or ARG/ADMA ratio in specific gastrointestinal conditions that require major abdominal surgery.
  3. To assess ADMA and the ARG/ADMA ratio in specific gastrointestinal conditions that require major abdominal surgery, pre and postoperatively.
  4. To identify whether amino acid (protein) and/or arginine intake affect plasma ADMA levels in the post-operative period and to incorporate this outcome in future randomised controlled trials investigation arginine supplementation and other nutritional interventions.

Parents of potential participants will be approached preoperatively or up to 5 days postoperatively to complete the informed consent process.

Once the parents of potential participants have had sufficient time to read and process the information regarding the study (minimum 2 hours), and sufficient time to ask questions regarding the study, written consent will be obtained.

Blood samples will be taken by the clinical team routinely as part of their clinical care. Patients will be managed as per accepted clinical practice and local clinical guidelines by the clinical team. There will be no changes from routine practice due to the SuNDiAL study. No extra blood tests will be taken for the SuNDiAL study.

If an infant is eligible and the parents have given consent to participate in the SuNDiAL study, at the time of ordering routine clinical blood tests the clinical team will order an additional dummy blood test 'SUNDIAL store sample'.

If there is any remaining serum following routine clinical blood tests, the 'SUNDIAL store sample' will alert the lab to store the blood sample for the SuNDiAL study. The sample will frozen and be stored in the SuNDiAL area of the research laboratory freezer in Alder Hey Children's Hospital. All samples with serum remaining will be stored. Samples will stop being stored once the patient is fully recovered or after 30 days post operatively which ever occurs first. The sample will be available for the clinical team to do further tests if these are required and this will take priority over testing the blood for research purposes.

Once there is sufficient samples to run an analysis the samples with be transported to the research laboratory. The samples will then be analysed by the ELISA technique, to measure Arginine and ADMA. Samples will be anonymised by the research team prior to being transported to the Research Laboratory in the Institute in the park at Alder Hey Children hospital.

The data will be anonymised prior to analysis. Data will be analysed for both the primary and secondary outcomes outlined above by the University of Liverpool Computational Biological Facility.

02

Conditions studied

  • Gastroschisis
  • Congenital Diaphragmatic Hernia
  • Duodenal Atresia
  • Oesophageal Atresia With Tracheo-Oesophageal Fistula
  • Oesophageal Atresia
  • Exomphalos

Keywords

  • Neonatal
  • Abdominal Surgery
  • Asymmetric Dimethylarginine
  • ADMA
  • Arginine
  • Recovery
  • Neonate
03

In context

Gastroschisis

42 studies on the registry are indexed under Gastroschisis; 6 are open to participants now.

This study's planned enrollment of 30 is below the median of 53 across 14 observational studies indexed under Gastroschisis.

Browse Gastroschisis studies →

Lead sponsor

Liverpool Women's NHS Foundation Trust is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 5 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population with be of 30 infants born >35 weeks gestation and has a condition requiring major gastrointestinal surgery within 5 days (120 hours) of birth. This is expected to include predominantly congenital gut malformations: gastroschisis, gut atresias, volvulus and congenital diaphragmatic hernia (who are stable enough for surgery in this time frame).

Patient will be recruited over a 1 year period. These infants will be born at Liverpool Women's Hospital or at their local hospital in the north west of England region, and transferred to Alder Hey Children's Hospital for their operation, either directly or via Liverpool Women's Hospital Neonatal Intensive Care Unit. They will recover in Alder Hey Children's Hospital's Paediatric Intensive Care Unit or Neonatal Surgical Unit and may later be transferred back to Liverpool Women's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants born >35 weeks gestation
  2. Have a condition requiring major gastrointestinal surgery
  3. Surgery within the first 5 days (120 hours) following birth (including congenital diaphragmatic hernia who are stable enough for surgery in this time frame).
  4. Parent(s)/guardian(s) must have a comprehensive understanding of written and spoken English, sufficient to provide informed using the translation services available to the research team.
  5. Must be willing and able to provide in order to take part in the study

Exclusion criteria

Exclusion Criteria:

  1. Infants who are unlikely to survive because of poor immediate postoperative condition.
  2. Infants known (or suspected to have) a diagnosis of inborn error of metabolism or serious liver dysfunction.
  3. Parent(s)/guardian(s) who are unable to give .
  4. Infants who it is not possible to obtain the minimum required residual serum samples from routine biochemical blood testing as outlined in the study schedule
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Study Population

    Infants born \>35 weeks gestation and have a condition requiring major gastrointestinal surgery within 5 days (120 hours) of birth. This is expected to include predominantly congenital gut malformations such as gastroschisis, gut atresias, volvulus and congenital diaphragmatic hernia (who are stable enough for surgery in this time frame).

    Procedure: Abdominal Surgery for congenital gut malformation in the first 5 days of life.

Interventions

  • ProcedureAbdominal Surgery for congenital gut malformation in the first 5 days of life.

    Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.

06

What researchers measure

Primary outcomes

  1. The relationship between Arginine, ADMA and the Arginine to ADMA ratio in comparison to the time taken to recover from abdominal surgery.

    The primary outcome measure will investigate the level of plasma ADMA, arginine and ARG/ADMA ratio preoperatively and in the immediate postoperative period (5 days) in infants stratified according to typical (\<21 days) or prolonged (\>21 days) postoperative PN dependency. The following measures will be compared between the typical and prolonged recover groups: 1. The pre-operative level (peak/trough as appropriate) of Arginine, ADMA and the ARG/ADMA ratio. 2. The post-operative level (peak/trough as appropriate) within 5 days of surgery of arginine, ADMA and the ARG/ADMA ratio and its relationship to postoperative PN days. 3. The maximum per-infant difference between pre-operative and post-operative levels as defined in a) and b).

    Time frame: From Enrolment to 30 days following surgery

Secondary outcomes

  1. Develop a mathematical model to describe the entire postoperative (30 days) trajectory of Arginine, ADMA and the ARG/ADMA ratio in relation to PN dependency.

    Time frame: From enrolment until day 30 post operatively.

  2. To study the relationship over time between nutritional intake and arginine, ADMA and the ARG/ADMA ratio.

    Time frame: From enrolment until day 30 postoperatively.

  3. The relationship over time between clinically monitored postoperative inflammatory and biochemical markers and arginine, ADMA and the ARG/ADMA ratio

    Time frame: From Enrolment to 30 days post operatively

  4. Impact of individual episodes (including duration) of any recognised postoperative complication (eg wound complications, bowel complications, sepsis) on the recovery time and the mathematical model described above.

    Time frame: From enrolment to 30 days post operation

  5. Weight Gain/head growth over the study period in relationship to Arginine, ADMA and Arginine to ADMA ratio.

    Time frame: Enrolment to 30 days post operation.

  6. Level of care and major treatments (eg ventilation, inotropic support, antibiotics for sepsis) during the study period in relation to Arginine, ADMA and the Arginine to ADMA ratio.

    Time frame: From enrolment to 30 days postoperatively.

07

Study locations

2 of 2 sites recruiting
  • Alder Hey Childrens Hospital NSH Foundation Trust
    Liverpool, Merseyside L12 2AP, United Kingdom
    Recruiting
    • Colin Morgan, BMedSci BM BS MRCP FRCPCH MD · Contactcolin.morgan@lwh.nhs.uk · +447842153126
    • Joshua Stead, MBChB MPhil MRCPCH · Contactjoshua.stead@nhs.net · +447532068608
    • Joshua Stead, MBChB MPhil MRCPCH · Principal investigator
  • Liverpool Womens Hospital NHS Foundation Trust
    Liverpool, Merseyside L8 7SS, United Kingdom
    Recruiting
    • Colin Morgan, BMedSci BM MRCP FRCPCH MD · Contactcolin.morgan@lwh.nhs.uk · +447842153126
    • Joshua Stead, MBChB MPhil MRCPCH · Contactjoshua.stead@nhs.net · +447532068608
    • Joshua Stead, MBChB MPhil MRCPCH · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06731855
Lead sponsor
Liverpool Women's NHS Foundation Trust
Collaborators
Alder Hey Children's NHS Foundation Trust
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Feb 5, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Sep 29, 2025

Study contacts

Colin Morgan
Contact
colin.morgan@lwh.nhs.uk
0151 7024382
Joshua Stead
Contact
joshua.stead@nhs.net
0151 7024382

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion